AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1c) levels by analysing the respective contributions of fasting hyperglycaemia (FHG), also referred to as basal hyperglycaemia, vs postprandial hyperglycaemia (PHG) before and after initiation of a basal or premixed insulin regimen in patients with type 2 diabetes. METHODS: This post-hoc analysis of insulin-naive patients in the DURABLE study randomised to receive either insulin glargine or insulin lispro mix 25 evaluated the percentages of patients achieving a target HbA1c of <7.0% (<53mmol/mol) per baseline HbA1c quartiles, and the effect of each insulin regimen on the relative contributions of PHG and FHG to overall hyperglycaemia. RESULTS:...
Basal insulin treatment for type 2 diabetes is usually initiated on a background of oral glucose-low...
AbstractAimsTo investigate treatment patterns and achievement of glycemic targets in patients with t...
AIM: To investigate whether the change in glycated albumin 3 weeks after initiating anti-diabetes tr...
AIMS: To describe in a real-world setting the achievement of physician-selected individualized HbA1c...
This sub-analysis of the Iran-AFECT study was to determine the baseline characteristics are predicti...
OBJECTIVEdTo determine the relative contributions of basal hyperglycemia (BHG) versus postprandial h...
BACKGROUND: When target glycated hemoglobin (HbA1C) levels are not reached, basal insulin therapy sh...
AIMS: The aim of this analysis was to assess the efficacy and safety of intensifying insulin therapy...
AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
The incidence of type 2 diabetes is reaching pandemic proportions, impacting patients and healthcare...
Karel Kostev,1 Franz W Dippel,2 Wolfgang Rathmann3 1IMS Health, Frankfurt, 2Sanofi-Aventis Deutschla...
AIMS: To evaluate short- and long-term glycaemic control and hypoglycaemia incidence in insulin-naïv...
AIMS: To identify HbA1c trajectories after the start of insulin treatment and to identify clinically...
AIMS: To evaluate short- and long-term glycaemic control and hypoglycaemia incidence in insulin-naïv...
Aims: To identify subgroups of patients with type 2 diabetes mellitus (T2DM) following distinct traj...
Basal insulin treatment for type 2 diabetes is usually initiated on a background of oral glucose-low...
AbstractAimsTo investigate treatment patterns and achievement of glycemic targets in patients with t...
AIM: To investigate whether the change in glycated albumin 3 weeks after initiating anti-diabetes tr...
AIMS: To describe in a real-world setting the achievement of physician-selected individualized HbA1c...
This sub-analysis of the Iran-AFECT study was to determine the baseline characteristics are predicti...
OBJECTIVEdTo determine the relative contributions of basal hyperglycemia (BHG) versus postprandial h...
BACKGROUND: When target glycated hemoglobin (HbA1C) levels are not reached, basal insulin therapy sh...
AIMS: The aim of this analysis was to assess the efficacy and safety of intensifying insulin therapy...
AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
The incidence of type 2 diabetes is reaching pandemic proportions, impacting patients and healthcare...
Karel Kostev,1 Franz W Dippel,2 Wolfgang Rathmann3 1IMS Health, Frankfurt, 2Sanofi-Aventis Deutschla...
AIMS: To evaluate short- and long-term glycaemic control and hypoglycaemia incidence in insulin-naïv...
AIMS: To identify HbA1c trajectories after the start of insulin treatment and to identify clinically...
AIMS: To evaluate short- and long-term glycaemic control and hypoglycaemia incidence in insulin-naïv...
Aims: To identify subgroups of patients with type 2 diabetes mellitus (T2DM) following distinct traj...
Basal insulin treatment for type 2 diabetes is usually initiated on a background of oral glucose-low...
AbstractAimsTo investigate treatment patterns and achievement of glycemic targets in patients with t...
AIM: To investigate whether the change in glycated albumin 3 weeks after initiating anti-diabetes tr...